RxDoctor Payments Data

Marshall Morrison, MD

Internal Medicine · Azle, TXNPI 1508836099

Payments from drug & device makers

$6,280in general payments, 2019–2025

Across 383 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boehringer Ingelheim$605
  • Pfizer$569
  • GSK$552
  • AstraZeneca$449
  • Lilly USA, LLC$366
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,19499%
  • Education$861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,280 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$48,793
Medicare patients
211
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$106,320
OzempicSemaglutide69$65,200
JardianceEmpagliflozin64$52,760
MyrbetriqMirabegron63$37,192
XareltoRivaroxaban23$30,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$23,868
JanumetSitagliptin Phos/Metformin Hcl15$16,298
MounjaroTirzepatide14$14,879
FarxigaDapagliflozin Propanediol20$12,963
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$8,030
Potassium Chloride184$6,151
Gabapentin226$5,274
Dexlansoprazole DrDexlansoprazole14$4,357
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,335
Levothyroxine Sodium372$4,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$569$106,320126 claims
Novo NordiskOzempic$330$65,20069 claims
Boehringer IngelheimJardiance$605$52,76064 claims
Astellas Pharma US IncMyrbetriq$221$37,19263 claims
Johnson & JohnsonXarelto$86$30,46823 claims
GSKTrelegy Ellipta$552$23,86838 claims
Lilly USA, LLCMounjaro$366$14,87914 claims
AstraZenecaFarxiga$449$12,96320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Azle

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →